MHRA-102258-PIP01-25

Key Facts

Active Substance
  • LEVODOPA
  • CARBIDOPA MONOHYDRATE
Invented Name
Crexont
PIP Number MHRA-102258-PIP01-25
Pharmaceutical form(s)
Pharmaceutical form(s):
  • Modified-release capsule, hard
Therapeutic area
Therapeutic area:
  • Neurology
Conditions / Indications
Conditions / Indications:
  • Treatment of Parkinson’s disease
Route(s) of administration
Route(s) of administration:
  • Oral use
PIP applicant
Decision Type
Decision Type
W: decision granting a waiver in all age groups for the listed condition(s).
Compliance Check
Compliance Check
No
Compliance Check Decision Date
Compliance Check Procedure Number

Decision Document

Decision Document Decision Document on a Paediatric Investigation Plan (PIP):LEVODOPACARBIDOPA MONOHYDRATE.pdf
Published Date 06/07/2026